Clinical Trial Update: Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance [NA]

View source ↗

Summary

A completed clinical trial evaluated the effect of PACAP38 and vasoactive intestinal peptide on migraineurs, using MRI to assess outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Without Aura

Drugs mentioned

• PACAP38 (pituitary adenylate cyclase-activating polypeptide-38)
• Vasoactive intestinal peptide (vasoactive intestinal peptide)

Snippet

Sponsor: Glostrup University Hospital, Copenhagen | Conditions: Migraine Without Aura | NA | Status: COMPLETED